Organogenesis (ORGO) Competitors $4.58 -0.17 (-3.58%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$4.74 +0.16 (+3.38%) As of 09/19/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGO vs. MLYS, IBRX, CPRX, ALVO, OCUL, BLTE, IDYA, AGIO, ANIP, and RXRXShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), Catalyst Pharmaceuticals (CPRX), Alvotech (ALVO), Ocular Therapeutix (OCUL), Belite Bio (BLTE), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), ANI Pharmaceuticals (ANIP), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Its Competitors Mineralys Therapeutics ImmunityBio Catalyst Pharmaceuticals Alvotech Ocular Therapeutix Belite Bio IDEAYA Biosciences Agios Pharmaceuticals ANI Pharmaceuticals Recursion Pharmaceuticals Organogenesis (NASDAQ:ORGO) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment. Is ORGO or MLYS more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -1.92%. Organogenesis' return on equity of -0.37% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-1.92% -0.37% -0.20% Mineralys Therapeutics N/A -70.44%-65.51% Which has more volatility & risk, ORGO or MLYS? Organogenesis has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500. Do institutionals & insiders hold more shares of ORGO or MLYS? 49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 33.0% of Organogenesis shares are owned by company insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate ORGO or MLYS? Organogenesis currently has a consensus target price of $7.50, suggesting a potential upside of 63.76%. Mineralys Therapeutics has a consensus target price of $43.50, suggesting a potential upside of 10.77%. Given Organogenesis' higher probable upside, equities research analysts clearly believe Organogenesis is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has preferable valuation & earnings, ORGO or MLYS? Organogenesis has higher revenue and earnings than Mineralys Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$482.04M1.21$860K-$0.14-32.71Mineralys TherapeuticsN/AN/A-$177.81M-$3.56-11.03 Does the media favor ORGO or MLYS? In the previous week, Mineralys Therapeutics had 10 more articles in the media than Organogenesis. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 1 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.73 beat Mineralys Therapeutics' score of 0.57 indicating that Organogenesis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Mineralys Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryOrganogenesis beats Mineralys Therapeutics on 9 of the 15 factors compared between the two stocks. Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$602.57M$2.58B$5.79B$10.40BDividend YieldN/A55.37%5.63%4.60%P/E Ratio-32.7122.7276.4826.75Price / Sales1.21689.96531.95124.23Price / Cash22.76175.2537.9261.55Price / Book2.195.3513.726.40Net Income$860K$32.95M$3.29B$271.62M7 Day Performance-7.10%0.90%1.03%2.85%1 Month PerformanceN/A6.78%6.32%9.64%1 Year Performance61.84%-3.47%81.16%31.62% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis3.9145 of 5 stars$4.58-3.6%$7.50+63.8%+56.3%$602.57M$482.04M-32.71950Positive NewsMLYSMineralys Therapeutics2.5149 of 5 stars$36.21-2.4%$43.50+20.1%+224.5%$2.46BN/A-10.1728Insider TradeIBRXImmunityBio2.3465 of 5 stars$2.74+5.4%$10.75+292.3%-21.6%$2.46B$14.74M-5.71590High Trading VolumeCPRXCatalyst Pharmaceuticals4.9446 of 5 stars$19.76-1.1%$33.20+68.0%-7.4%$2.44B$491.73M11.9880Positive NewsALVOAlvotech3.3557 of 5 stars$8.12+1.1%$14.00+72.4%-29.5%$2.42B$491.98M35.301,032News CoverageShort Interest ↓OCULOcular Therapeutix3.8865 of 5 stars$12.54-2.1%$17.83+42.2%+33.8%$2.23B$63.72M-9.80230Positive NewsBLTEBelite Bio2.8357 of 5 stars$66.80-3.9%$96.00+43.7%+44.6%$2.21BN/A-43.1010News CoverageAnalyst UpgradeAnalyst RevisionHigh Trading VolumeIDYAIDEAYA Biosciences3.9879 of 5 stars$24.53-0.3%$42.85+74.7%-27.0%$2.16B$7M-6.4780Analyst ForecastAGIOAgios Pharmaceuticals4.3093 of 5 stars$36.30-1.3%$56.00+54.3%-20.4%$2.14B$36.50M3.30390ANIPANI Pharmaceuticals4.0302 of 5 stars$98.81+1.1%$88.25-10.7%+60.3%$2.12B$614.38M-128.32600Positive NewsAnalyst ForecastAnalyst RevisionRXRXRecursion Pharmaceuticals2.1328 of 5 stars$4.77-1.2%$7.25+52.0%-29.3%$2.10B$58.84M-2.68400Positive News Related Companies and Tools Related Companies Mineralys Therapeutics Alternatives ImmunityBio Alternatives Catalyst Pharmaceuticals Alternatives Alvotech Alternatives Ocular Therapeutix Alternatives Belite Bio Alternatives IDEAYA Biosciences Alternatives Agios Pharmaceuticals Alternatives ANI Pharmaceuticals Alternatives Recursion Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGO) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
